To review and update the pharmacology, pharmacokinetics, safety, precautions, efficacy, and use of abatacept for rheumatoid arthritis (RA).
Data Sources:
Studies and abstracts were identified through MEDLINE, International Pharmaceutical Abstracts, Cochrane databases, and Science Citation Index (1990–April 2007). Key search terms included abatacept, CTLA4–Ig, and BMS 1888667. Information available only in abstract form was retrieved from national and international rheumatology associations. Additional data were obtained from the manufacturer.
Study Selection and Data Extraction:
All available animal and human studies describing the pharmacology of abatacept and human studies describing the pharmacokinetics, pharmacodynamics, efficacy, safety, adverse events, and precautions of abatacept were included.
Data Synthesis:
Abatacept significantly improves the signs and symptoms of moderate-to-severe RA in patients who experienced an Inadequate response to methotrexate or antitumor necrosis factor-α inhibitors. By month 12, approximately 50% of patients achieved remission (defined as a disease activity score <2.6) that was maintained until at least 24 months of therapy. The most common adverse events include headache, upper respiratory tract infections, nausea, and nasopharyngitis. Rare but serious adverse events include serious infections and malignancy.
Conclusions:
Abatacept has documented efficacy and safety in patients with inadequate responses to methotrexate and antitumor necrosis factor agents in both short- and long-term studies. Additional clinical trial and postmarketing evidence is necessary to understand the long-term safety, efficacy, economics, and rote of abatacept in clinical practice.
DoanT, MassarottiE. Rheumatoid arthritis: an overview of new and emerging therapies. J Clin Pharmacol2005; 45:751–62.
2.
GaffoA, SaagKG, CurtisJR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm2006; 63:2451–65.
3.
BreedveldFC, KaldenJR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis2004; 63:627–33.
4.
O'DellJR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med2004; 350:2591–602.
5.
OlsenNJ, SteinCM. New drugs for rheumatoid arthritis. N Engl J Med2004; 350:2167–79.
6.
MarietteX. Emerging biological therapies in rheumatoid arthritis. Joint Bone Spine2004; 71:470–4.
7.
PanayiGS, CorrigallVM, PitzalisC. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am2001; 27:317–34.
8.
ChoyEH, PanayiGS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med2001; 344:907–16.
9.
BuddRC, FortnerKA. T Lymphocytes. In: HarrisED, BuddRC, FiresteinGS, eds. Kelley's textbook of rheumatology. 7th ed.Philadelphia: Elsevier/Saunders, 2005: 133–52.
10.
KremerJM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol2005; 11(suppl):S55–62.
11.
KremerJM. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin North Am2004; 30:381–91.
12.
Package insert.Orencia (abatacept)Princeton, NJ: Bristol-Myers Squibb Co., December 2005.
13.
DavisP, NadlerS, SuchardS. Abatacept differentially modulates B-cell and dendritic cell-stimulated T cell effector function (abstract). Ann Rheum Dis2006; 64:400.
14.
EmeryP, WesthovensR, LeonG. Beneficial effects of the selective co-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment (abstract). Ann Rheum Dis2005; 64:1407.
15.
WeismanMH, DurezP, HalleguaD. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol2006; 33:2162–6.
16.
MorelandLW, AltenR, Van den BoschF. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum2002; 46:1470–9.
17.
KremerJM, WesthovensR, LeonM. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med2003; 349:1907–15.
18.
GenoveseMC, BeckerJC, SchiffM. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med2005; 353:1114–23.
19.
KremerJM, DougadosM, EmeryP. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelvemonth results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum2005; 52:2263–71.
20.
KremerJM, GenantHK, MorelandLW. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med2006; 144:865–76.
21.
WeinblattME, SchiffMH, GoldmanA. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis2007; 66:228–34. Epub 2006 Aug 25. DOI 10.1136/ard.2006.055111
22.
KremerJ, ShergyW, TindallE. Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate (abstract). Arthritis Rheum2004; 50:S182.
23.
KremerJ, EmeryP, BeckerJP. Abatacept provides significant and sustained benefits in clinical and patient-reported outcomes through 2 yrs in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX): the long-term extension (LTE) of the AIM trial (abstract). Ann Rheum Dis2006; 65:S327.
24.
FelsonDT, AndersonJJ, BoersM. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum1995; 38:727–35.
25.
EmeryP, KosinskiM, LiT. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of Ufe. J Rheumatol2006; 33:681–9.
26.
DougadosM, WesthovensR, St ClairEW. Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate (abstract). Arthritis Rheum2004; 50:S185.
27.
WesthovensR, EmeryP, ArandaR, BeckerJP, ZhouY, DougadosM. Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis (RA) patients with inadequate responses to methotrexate (MTX) (abstract). Ann Rheum Dis2006; 65:S512.
28.
SibiliaJ, SchiffM, GenoveseMC. Sustained improvements in disease activity score 28 (DAS28) and patient (PT)-reported outcomes (PRO) with abatacept (ABA) in rheumatoid arthritis (RA) pts. with an inadequate response to anti-TNF therapy: the long-term extension (LTE) of the ATTAIN trial (abstract). Ann Rheum Dis2006; 65:S501.
29.
WeinblattM, CombeB, CovucciA, ArandaR, BeckerJC, KeystoneE. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum2006; 54:2807–16.
30.
RupertoN, LovellDJ, PrieurA. Efficacy and safety of abatacept in children and adolescents with active juvenile arthritis (JIA) (abstract). Ann Rheum Dis2006; 65:248.
31.
AbramsJR, KelleySL, HayesE. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4–immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med2000; 192:681–94.
32.
Abatacept in the treatment and prevention of active systemic lupus erythematosus (SLE) flares in combination with prednisone.National Library of Medicine. http://clinicaltrials.gov/ct/show/NCT00119678 (accessed 2007 Mar 13).
33.
MorelandLW, CombeB, SteinfeldS. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies (abstract). Ann Rheum Dis2006; 65:S110.
34.
Amezcua-GuerraLM, Hernandez-MartinezB, PinedaC, BojalilR. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut2006; 55:1059–60.
35.
HaggertyHG, AbbottMA, ReillyTP. Abatacept displays low levels of immunogenicity in the treatment of rheumatoid arthritis (abstract). Ann Rheum Dis2006; 65:S319.
HaggertyH, BigbeeC, GonchoroffD, FlynnJ. Abatacept treatment does not impair host resistance to chronic Mycobacterium tuberculosis infection in mice (abstract). Ann Rheum Dis2006; 65:319a.
38.
SimonTA, SmittenAL, BoodhooT. Observed and expected malignancies in the abatacept clinical development program: an epidemiological assessment (abstract). Ann Rheum Dis2006; 65:S489.
39.
CorboM, TayL, LeonF, VratsanosG. A single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines (abstract). Ann Rheum Dis2006; 65:184.
40.
DaviesA, CifaldiMA, WeismanM, SeguradoOG. Cost effectiveness of the 3 TNF antagonists vs abatacept in the treatment of moderate to severe rheumatoid arthritis (RA) (abstract). Ann Rheum Dis2006; 65:S278.
